A Phase 1 interventional study of Drug: NA-831 - 0.10 mg/kg and Placebo- 0.10 mg/kg in Covid19, Corona Virus Infection and Severe Acute Respiratory Syndrome, sponsored by Biomed Industries, Inc.. Status unknown at 1 site in United States. Open to participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2020-07-21.
Sponsored by Biomed Industries, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.
Among the 40 studies testing remdesivir in COVID-19, this one is the 37th largest by planned enrollment, is one of 27 that started in 2020, is one of 3 in phase 1, and was the 14th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
ANRS, Emerging Infectious Diseases · Sites in France, Italy, Norway
Ages 16+
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
Lebanese University · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 21 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 22 · Phase 4 5
First in 2016; this study’s year is marked. 27 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 283 across the 40 interventional studies. Of the 20 that completed or were terminated, 10 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 40 have an industry lead sponsor. The 10 most frequent:
Biomed Industries, Inc. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Biomed Industries, Inc. has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
4 of the studies testing remdesivir in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT07197164Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSafety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients | 2026-12-30 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies testing remdesivir in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers.
It has been discovered that SARS-CoV-2 viruses (Covid-19) can directly invade the nervous system of patients, instead of injuring the nervous system through the immune response. Neurotropism is one common feature of Covid-19. Such neuro-invasive propensity of Covid-19 has been documented almost for all the Beta-coronaviruses including SARS-CoV and MERS-CoV.
Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. It was observed that patients surviving COVID-19 are at high risk for subsequent development of neurological disease and in particular Alzheimer's disease.
NA-831 is a new neuroprotective and neurogenesis drug that has been demonstrated its promising safety and efficacy in Phase 2A for the treatment of early onset of Alzheimer's disease. NA-831 in oral formulation is well tolerated NA-831 with no adverse effects. NA-831 in oral formulation exhibits predictable pharmacokinetics including dose-dependent exposure linearity and low variability.
Based on animal studies, NA-831 can provide effective interventions during the severe acute respiratory syndrome, and provide appropriate rehabilitation measures afterwards.
Remdesivir (GS-5734) intravenous formulation has been approved by the FDA under the emergency use authorization for potential treatment of severe cases of Covid-19.
It was found the upper respiratory tract is the most prevalent site of SARS-CoV-2 infection early in disease. Delivering drugs directly to the primary site of infection with a nebulizer, inhaled nanoparticle formulation may enable more targeted and accessible administration in non-hospitalized patients and potentially lower systemic exposure to the drug.
The study is designed to evaluate the safety, tolerability and pharmacokinetics of a new nanoparticle formulation of Remdesivir (GS-5734) and combination therapy with NA-831 in healthy volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
Any condition that, in the opinion of the Investigator, would complicate or compromise the study or well-being of the subject.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 Subjects will take inhaled formulation of NA-831 once a day for 5 days
Drug: Drug: NA-831 - 0.10 mg/kg
3 subjects will take inhaled formulation of placebo once a day for 5 days
Drug: Placebo- 0.10 mg/kg
6 Subjects will take inhaled formulation of NA-831 once a day for 5 days
Drug: Drug: NA-831 - 0.20 mg/kg
3 subjects will take inhaled formulation of placebo once a day for 5 days
Drug: Placebo- 0.20 mg/kg
3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
Drug: Drug: GS-5734 - 1.00 mg/kg
3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
Drug: Placebo- 1.00 mg/kg
6 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
Drug: Drug: GS-5734 - 2.00 mg/kg
3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
Drug: Placebo- 2.00 mg/kg
3 Subjects- will take inhaled formulation NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) once/day for 5 days
Combination Product: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)
3 Subjects - inhaled formulation of placebo once/day for 5 days
Combination Product: Placebo 0.10 mg + 1.00 mg/kg
6 Subjects- inhaled formulation of NA-831 (0.20 mg/kg) + GS-5734 (2.00 mg/kg) once/day for 5 days
Combination Product: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)
3 Subjects- inhaled formulation of placebo once/day for 5 days
Combination Product: Placebo 0.20 mg + 2.00 mg/kg
Drug page: cyclo(prolylglycyl)
NA-831 in nanoparticle inhalation formulation
Also known as: NA-831 is a neuroprotective and neurogenesis drug
Placebo in nanoparticle inhalation formulation
Also known as: Placebo Comparator
Drug page: cyclo(prolylglycyl)
NA-831 in nanoparticle inhalation formulation
Also known as: NA-81 is a neuroprotective drug
Placebo in nanoparticle inhalation formulation
Also known as: Placebo Comparator
Drug page: Remdesivir
GS-5734 in nanoparticle inhaled formulation
Also known as: GS-5734 (Remdesivir) is an antiviral drug
Placebo in nanoparticle inhalation formulation
Also known as: Placebo Comparator
Drug page: Remdesivir
GS-5734 in nanoparticle inhaled formulation
Also known as: GS-5734 (Remdesivir) is an anti-viral drug
Placebo in nanoparticle inhaled formulation
Also known as: Placebo Comparator
Drug pages: cyclo(prolylglycyl) · Remdesivir
The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
Also known as: Combination therapy of NA-831 a neuroprotective drug and GS-5734 an antiviral drug
The combined placebo are in nanoparticle inhaled formulation
Also known as: Placebo Comparator
Drug pages: cyclo(prolylglycyl) · Remdesivir
The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
Also known as: Combination therapy of NA-831, a neuroprotective drug and GS-5734, an antiviral drug
Placebo 0.10 mg + 1.00 mg/kg
Also known as: Placebo Comparator
Proportion of Participants Experiencing any Treatment-Emergent Adverse Events
AEs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0
Time frame: First dose date up to Day 30 Follow-up Assessment
Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities
This will be assessed at various time points by clinical laboratory tests and vital signs.
Time frame: First dose date up to Day 30 Follow-up Assessment
Maximum Concentration (Cmax) - Pharmacokinetic Assessment
Monitoring of the levels of drugs in subject sera at various time points to elucidate the maximum concentration (Cmax) of NA-831 and GS-5734 in human serum.
Time frame: 7 days
Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment
Monitoring of the levels of drugs in subject sera at various time points to elucidate the time to maximum concentration (Tmax) of NA-831 and GS-5734 in human serum
Time frame: 7 days
AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment
Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve from time of administration to the last measurable of NA-831 and GS-5734
Time frame: 7 days
Area Under the Curve Extrapolated to Infinity (AUC0-∞)
Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve extrapolated to infinity (AUC0-∞) of NA-831 and GS-5734
Time frame: 7 days
Half-Life (t1/2) - Pharmacokinetic Assessment
Monitoring of the levels of drugs in subject sera at various time points to elucidate the half-life (t1/2) of NA-831 and GS-5734 in human serum.
Time frame: 7 days
Volume of Distribution (Vd) - Pharmacokinetic Assessment
Monitoring of the levels of drugs in subject sera through various time points to elucidate the volume of distribution (Vd) of NA-831 and GS-5734 in human serum.
Time frame: 7 days
Clearance [CL] - Pharmacokinetic Assessment
Monitoring of the levels of drugs in subject sera through at various time points to elucidate clearance \[CL\] of NA-831 and GS-5734 in human serum.
Time frame: 7 days
Plan to share: Yes — We plan to share the Study Protocol
Supporting information: Study protocol
Time frame: 90 days after the completion of the study
Access criteria: to be determined
No publications or documents are linked to this record.
Start is estimated for Sep 2020; primary completion for Dec 2020, 3 months later.
Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 3 months is below that.
Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: cyclo(prolylglycyl) · Remdesivir
Biomed Industries, Inc.